- Why are vegetarians more likely to suffer from depression than meat eaters?
- Small wireless device implanted between skin and skull helps kill cancer cells
- Will the mRNA vaccine that can cure cancer come out near soon?
- Allogeneic T-cell therapy set for landmark first approval
- Boston University denies that the new COVID strain they made has 80% fatality rate
- A new generation of virus-free CAR-T cell therapy
Peru resumes trials of Chinese COVID-19 vaccines
Peru resumes trials of Chinese COVID-19 vaccines. Peru approves SINOPHARM to resume trials of COVID-19 vaccine and will restart procurement negotiations.
Bloomberg News on December 17, Peru’s Minister of Health Pilar Mazzetti said that the Peruvian government allowed China Sinopharm Group to resume clinical trials of the COVID-19 vaccine on Wednesday.
Mazzetti said at a TV news conference that the government will now restart vaccine procurement negotiations with Sinopharm Group. The Peruvian government has signed a preliminary agreement with Pfizer for 9.9 million doses, but due to supply issues, it is expected that deliveries in 2021 will decrease.
According to “Global Times” previously reported by multiple foreign media on the 13th, the Peruvian Ministry of Health said on the 12th that because a volunteer had a health problem, it had suspended the clinical trials of the Sinopharm China Bio-COVID-19 inactivated vaccine in the country.
According to the Wall Street Journal, Dr. Germán Málaga, a researcher at the University of Cayetano Heredia in Peru, who conducted the vaccine trial, said that a 64-year-old volunteer had complications with “neurological symptoms” and decreased leg strength. , Some problems occurred in the operation.
However, Dr. Málaga told the local media RPP Noticias that he did not believe that the volunteer’s health problems were caused by the vaccine, but he needed more information.